News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
A road to survival
January 17, 2024
ASBMB Today
Read Now
Press Release
A road to survival
January 17, 2024
ASBMB Today
Read Now
Press Release
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
January 3, 2024
Read Now
Press Release
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
January 3, 2024
Read Now
Press Release
Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Read Now
Press Release
Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Read Now
News
Peer Review
December 21, 2023
Endpoints News
Read Now
Press Release
Peer Review
December 21, 2023
Endpoints News
Read Now
Press Release
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
December 20, 2023
Read Now
Press Release
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
December 20, 2023
Read Now